LUXTURNA targets the RPE65 gene to treat inherited retinal dystrophy, while Zolgensma targets the SMN1 gene in motor neurons to treat spinal muscular atrophy [75,80,81]. Here, SMN1 is linked to proximal spinal muscular atrophy.